# Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study

> **NCT04536558** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 352 (estimated)

## Conditions studied

- Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy

## Interventions

- **DRUG:** olanzapine plus fosaprepitant-based triple regimen
- **DRUG:** placebo plus fosaprepitant-based triple regimen

## Key facts

- **NCT ID:** NCT04536558
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-01
- **Primary completion:** 2021-02-01
- **Final completion:** 2021-03-30
- **Target enrollment:** 352 (ESTIMATED)
- **Last updated:** 2020-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04536558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04536558, "Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04536558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*